1. Home
  2. SRE vs NTRA Comparison

SRE vs NTRA Comparison

Compare SRE & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBA Sempra

SRE

DBA Sempra

N/A

Current Price

$76.60

Market Cap

56.3B

Sector

Utilities

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$274.96

Market Cap

56.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SRE
NTRA
Founded
1998
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.3B
56.7B
IPO Year
2008
2015

Fundamental Metrics

Financial Performance
Metric
SRE
NTRA
Price
$76.60
$274.96
Analyst Decision
Buy
Strong Buy
Analyst Count
21
23
Target Price
$96.44
★ $412.36
AVG Volume (30 Days)
★ 3.7M
2.0M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 3.45%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ 1.58
N/A
Revenue
★ $13,702,000,000.00
$210,939,000.00
Revenue This Year
N/A
$30.72
Revenue Next Year
N/A
$21.67
P/E Ratio
$48.28
★ N/A
Revenue Growth
★ 3.92
N/A
52 Week Low
$76.21
$181.00
52 Week High
$101.04
$437.41

Technical Indicators

Market Signals
Indicator
SRE
NTRA
Relative Strength Index (RSI) 31.67 24.66
Support Level $76.21 $254.83
Resistance Level $87.12 $288.04
Average True Range (ATR) 1.56 19.03
MACD -0.53 -7.70
Stochastic Oscillator 2.03 1.47

Price Performance

Historical Comparison
SRE
NTRA

About SRE DBA Sempra

Sempra serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure Partners, 25% owned by Sempra, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: